A Multi-Center Retrospective Study to Describe Clinical Characteristics and Outcomes of Early EVENITY Users, Transitioning to Antiresorptive Agents in Japan
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Romosozumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 10 Oct 2021 Planned End Date changed from 30 Apr 2021 to 13 Apr 2021.
- 10 Oct 2021 Status changed from not yet recruiting to active, no longer recruiting.